Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-Platelet Basic Protein (59-128) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.05% Proclin300, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:1000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
PPBP |
Gene ID: |
5473 |
Uniprot ID: |
CXCL7_HUMAN |
Immunogen Region: |
59-128 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 59-128 of human PPBP (NP_002695.1). |
Immunogen Sequence: |
AELRCMCIKTTSGIHPKNIQ SLEVIGKGTHCNQVEVIATL KDGRKICLDPDAPRIKKIVQ KKLAGDESAD |
Post Translational Modifications | Proteolytic removal of residues 1-9 produces the active peptide connective tissue-activating peptide III (CTAP-III) (low-affinity platelet factor IV (LA-PF4)). Proteolytic removal of residues 1-13 produces the active peptide beta-thromboglobulin, which is released from platelets along with platelet factor 4 and platelet-derived growth factor. NAP-2(1-66) is produced by proteolytical processing, probably after secretion by leukocytes other than neutrophils. NAP-2(73) and NAP-2(74) seem not be produced by proteolytical processing of secreted precursors but are released in an active form from platelets. |
Function | LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation. |
Protein Name | Platelet Basic ProteinPbpC-X-C Motif Chemokine 7Leukocyte-Derived Growth FactorLdgfMacrophage-Derived Growth FactorMdgfSmall-Inducible Cytokine B7 Cleaved Into - Connective Tissue-Activating Peptide IiiCtap-IiiLa-Pf4Low-Affinity Platelet Factor Iv - Tc-2 - Connective Tissue-Activating Peptide Iii(1-81Ctap-Iii(1-81 - Beta-ThromboglobulinBeta-Tg - Neutrophil-Activating Peptide 2(74Nap-2(74 - Neutrophil-Activating Peptide 2(73Nap-2(73 - Neutrophil-Activating Peptide 2Nap-2 - Tc-1 - Neutrophil-Activating Peptide 2(1-66Nap-2(1-66 - Neutrophil-Activating Peptide 2(1-63Nap-2(1-63 |
Database Links | Reactome: R-HSA-114608Reactome: R-HSA-380108Reactome: R-HSA-418594Reactome: R-HSA-6798695 |
Cellular Localisation | Secreted |
Alternative Antibody Names | Anti-Platelet Basic Protein antibodyAnti-Pbp antibodyAnti-C-X-C Motif Chemokine 7 antibodyAnti-Leukocyte-Derived Growth Factor antibodyAnti-Ldgf antibodyAnti-Macrophage-Derived Growth Factor antibodyAnti-Mdgf antibodyAnti-Small-Inducible Cytokine B7 Cleaved Into - Connective Tissue-Activating Peptide Iii antibodyAnti-Ctap-Iii antibodyAnti-La-Pf4 antibodyAnti-Low-Affinity Platelet Factor Iv - Tc-2 - Connective Tissue-Activating Peptide Iii(1-81 antibodyAnti-Ctap-Iii(1-81 - Beta-Thromboglobulin antibodyAnti-Beta-Tg - Neutrophil-Activating Peptide 2(74 antibodyAnti-Nap-2(74 - Neutrophil-Activating Peptide 2(73 antibodyAnti-Nap-2(73 - Neutrophil-Activating Peptide 2 antibodyAnti-Nap-2 - Tc-1 - Neutrophil-Activating Peptide 2(1-66 antibodyAnti-Nap-2(1-66 - Neutrophil-Activating Peptide 2(1-63 antibodyAnti-Nap-2(1-63 antibodyAnti-PPBP antibodyAnti-CTAP3 antibodyAnti-CXCL7 antibodyAnti-SCYB7 antibodyAnti-TGB1 antibodyAnti-THBGB1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance